Marshall Wace
LKFT icon

Marshall Wace’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Marshall Wace’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.33M Buy
78,456
+46,057
+142% +$1.32M ﹤0.01% 1739
2026
Q2 		$971K Buy
+32,399
New +$920K ﹤0.01% 2203
2026
Q1 		– Sell
-11,200
Closed -$366K – 3394
2025
Q4 		$366K Sell
11,200
-27,260
-71% -$880K ﹤0.01% 2376
2025
Q3 		$1.33M Buy
+38,460
New +$1.23M ﹤0.01% 1813
2024
Q3 		– Sell
-12,715
Closed -$315K – 2674
2024
Q2 		$315K Buy
+12,715
New +$361K ﹤0.01% 2130
2023
Q3 		– Sell
-43,615
Closed -$1.77M – 2380
2023
Q2 		$1.77M Buy
43,615
+30,776
+240% +$1.26M ﹤0.01% 1459
2023
Q1 		$496K Buy
+12,839
New +$528K ﹤0.01% 2102
2022
Q4 		– Sell
-17,149
Closed -$732K – 3113
2022
Q3 		$732K Buy
+17,149
New +$879K ﹤0.01% 2557
2022
Q1 		– Sell
-6,225
Closed -$344K – 3580
2021
Q4 		$344K Buy
+6,225
New +$325K ﹤0.01% 2975
2020
Q3 		– Sell
-4,772
Closed -$941K – 1708
2020
Q2 		$941K Buy
+4,772
New +$988K 0.01% 1012
2019
Q4 		– Sell
-1,732
Closed -$264K – 1838
2019
Q3 		$264K Buy
+1,732
New +$284K ﹤0.01% 1234
2019
Q2 		– Sell
-23,767
Closed -$2.8M – 1528
2019
Q1 		$2.8M Sell
23,767
-69,991
-75% -$7.06M 0.03% 646
2018
Q4 		$8.6M Sell
93,758
-42,494
-31% -$4.31M 0.09% 289
2018
Q3 		$15.3M Buy
+136,252
New +$14.4M 0.13% 211
2018
Q2 		– Sell
-42,649
Closed -$4.26M – 747
2018
Q1 		$4.26M Buy
+42,649
New +$4.6M 0.18% 116
2017
Q1 		– Sell
-7,340
Closed -$471K – 466
2016
Q4 		$471K Buy
7,340
+1,311
+22% +$80.7K ﹤0.01% 847
2016
Q3 		$390K Buy
+6,029
New +$340K ﹤0.01% 829

Other funds holding LKFT

Gilead Sciences
Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return
Prosight Management
Prosight Management Dallas, Texas $515M AUM 2.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Marshall Wace's LKFT Position: Q3 2026 in Review

Marshall Wace increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 142% in Q3 2026, buying an estimated $1.32M and bringing the position to 78,456 shares worth $2.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1739.

Marshall Wace first reported a position in LKFT in Q3 2016 and has held it in 17 quarters since. The position peaked at $15.3M in Q3 2018. 67 funds tracked by Wall St. Rank hold LKFT as of Q3 2026.

  • Marshall Wace held 78,456 shares of Lakefront Biotherapeutics American Depositary Shares worth $2.33M as of Q3 2026.
  • Marshall Wace bought 46,057 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2026, an estimated $1.32M.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Marshall Wace's portfolio in Q3 2026, its #1739 holding.
  • Marshall Wace first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2016 and has held it in 17 quarters since.
  • Marshall Wace's Lakefront Biotherapeutics American Depositary Shares position peaked at $15.3M in Q3 2018.
  • 67 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2026.

Based on Marshall Wace's 13F filing for Q3 2026, filed 13 Nov 2026.